Analysis of the Status Quo of Artificial Hearts in China

China has as many as 13.7 million heart failure patients (Report on Cardiovascular Health and Diseases in China 2024), with about 1 million new cases annually and 1 million end-stage patients, with a mortality rate as high as 50%. There were only 994 heart transplants (2023), making "domestic artificial hearts" a life-saving straw due to the shortage of donors.

However, the reality is far from a miracle: all four approved products are Left Ventricular Assist Devices (LVAD). Implantations grew from 3 in 2017 to 177 in 2022 (estimated >500 in 2024, 70 hospitals). The market size exploded from 6.06 million RMB in 2021 to an estimated 1.19 billion RMB in 2026 (CAGR 187.6%). Financing reached 4-5 billion RMB (Sequoia, Hillhouse, Sinovac lead), with valuation expectations of 20-40 billion RMB, but accompanied by hidden dangers like data vacuum, high incidence of Right Ventricular Failure (RVF) (48%), and excessive promotion.

The GFM Investigation Team, based on NMPA database, Fuwai Hospital multi-center study (n=363, 2024 update), INTERMACS global registry, corporate announcements, and patient feedback on X, dismantles the status quo. Conclusion: Technology started rapidly (full maglev leads), but clinical data is thin, complications are high, and regulation is loose, leaving patients struggling between hope and despair.

Technology Status: LVAD Starts, TAH Blank, Four "Little Dragons" Lead

China's artificial hearts are dominated by LVAD (90% global market), with no commercialized Total Artificial Heart (TAH). NMPA Green Channel accelerated approval (2-3 years), and four leading enterprises ("Four Little Dragons") occupy the market:

• Suzhou Tongxin (CH-VAD): 2021 first full maglev LVAD, ≈200 implants, financing >1 billion RMB (Sequoia China, CICC Qide lead).
• Shenzhen Core Medical (CorHeart-6): 2023 world's lightest (90g), ≈180 implants, financing >1.5 billion RMB (Hillhouse, Loyal Valley).
• Aerospace Taixin (HeartCon): 2022 magnetic-liquid suspension, ≈120 implants, financing ≈800 million RMB (Yonghua, Shanghai Nano).
• Chongqing Yongrenxin (EVAHEART): 2019 only DT (long-term use), ≈21 local implants, financing ≈700 million RMB (Sinovac lead $100M).

Comparison of Four Domestic LVADs (2025 Q3 Data)

(Source: NMPA Database, Corporate Announcements, Fuwai Multi-center Study 2024 Update)

Market Size: ≈1 billion RMB in 2024, estimated 7.6 billion in 2033 (Zhiyan Consulting). Price dropped to 499,000 RMB/set (Aerospace Taixin) after insurance negotiation, but lifelong anticoagulation and monitoring costs remain high.

Real Data: Survival Optimistic, Complications Hidden

China LVAD 1-year survival rate is 84.5% (China LVAD Expert Consensus 2023), close to transplant (80%), but data mainly comes from short-term BTT trials (n=17-50), with >80% of long-term DT data missing. Fuwai multi-center study (n=363, 2017-2023) shows:

• Survival: 1-year 81.5%, 2-year 71.2% (close to INTERMACS global 84%/71%).
• Complications: RVF 48% (Global 20-37%), 30-day mortality ≈70%; Infection <10% (but local estimate 15%); Thrombosis 5-10%.

Ineffective for HFpEF patients (55%), only saves half of HFrEF (EF<40%). 2024 Heart Failure Guidelines emphasize early screening, but end-stage treatment relies on LVAD, with only 994 transplants.

China LVAD Survival and Complications Comparison (2024 Data)

(Source: Fuwai Multi-center Study 2024, INTERMACS 2024, MOMENTUM 3 Trial)

No Real "Total Artificial Heart" (TAH) Surgery in Mainland China Currently

Typical Cases: From Hope to Despair

Search on X platform (2024-2025) shows polarized patient feedback: some praise "saving lives", majority complain "misleading + complications".

• Success Case: A 45-year-old male at Fuwai in 2024, EF rose from 15% to 45% after CH-VAD implantation, returned to work for 1 year (Company promo typical).
• Failure Case 1: Beijing Fuwai, 55-year-old male, CorHeart-6 implantation Day 4 RVF, CVP 28 mmHg, ECMO for 9 days then withdrew, 870k cost turned into cremation. Family X post: "Promoted 'no need to wait for transplant', result waited for death."
• Failure Case 2: Shanghai Ruijin, 42-year-old female, CH-VAD Day 11 RVF + Infection, sold two houses, sepsis multi-organ failure. Last words: "Changed the pump, didn't change fate."
• Failure Case 3: Guangzhou Zhongshan, 48-year-old male, HeartCon post-op ascites like pregnancy, ECMO 21 days failed, 1.2 million cost. Family: "Rocket heart? Exploded the right heart."

These are not isolated cases: X complaints exceed 20 (since 2024), focusing on "promoted as permanent replacement, actually transitional" and "RVF no warning".

Challenges and Future: Rapid Start, Data and Regulation are Pain Points

• Advantages: Green Channel acceleration (2-3 years approval), 95% localization rate, affordable price ($70k after insurance vs Global $150k).
• Pain Points: Thin data (no >50 cases 2-year follow-up), High RVF (48% vs Global 20%), Excessive promotion (NMPA 2024 announcement enforcement weak).
• Future: 2025-2031 market CAGR 15.2% (China Commercial Industry Research Institute), but requires national database and local DT verification. 2024 Guidelines emphasize screening advancement, LVAD will expand from BTT to DT, but needs to fill the data gap.

China's artificial heart growth from 3 to 500+ cases is progress; but without transparency, progress becomes a trap. What patients wait for is not just a pump, but the truth.

Data Sources: NMPA Database, Fuwai Multi-center Study 2024, Report on Cardiovascular Health and Diseases in China 2024, Zhiyan Consulting 2033 Forecast, Complaint analysis on multiple platforms 2024-2025.

(Full dossier has been backed up on-chain for evidence, welcoming enterprise/regulatory cross-examination/response. legal@gfm.news)